The "Global Cancer Tubulin Inhibitors Market Clinical Trial Insight 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
Global Cancer Tubulin Inhibitors Market Clinical Trial Insight 2024 report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy. Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market.
Global Cancer Tubulin Inhibitors Market Clinical Trial Insight 2024 Report highlights:
- Clinical Insight on 70 Tubulin Inhibitors in pipeline
- Dosage Price Analysis of 10 Commercialized Drugs
- Patent Approval, Expiry Year Market Sales Indicators
- Patent Analysis of Key Drugs
- Global Cancer Tubulin Inhibitors Clinical Pipeline by Company Phase
- Future Perspective of Cancer Tubulin Inhibitors
Key Topics Covered:
1. Microtubules Moving Target in Cancer Therapy
2. Mechanism of Action Mechanism of Resistance of Tubulin Inhibitors
3. Microtubules Their Role in Cellular Stress in Cancer
4. Prognostic Role of Tubulin for Prediction of Cancer Aggressiveness
5. Price Dosage Analysis of Tubulin Inhibitor Drugs
6. Market Analysis of Tubulin Inhibitors
7. Global Cancer Tubulin Inhibitors Clinical Pipeline Overview
8. Global Cancer Tubulin Inhibitors Clinical Pipeline by Company Phase
9. Marketed Cancer Tubulin Inhibitors Clinical Insight
10. Global Cancer Tubulin Inhibitors Market Dynamics
11. Future Perspective of Cancer Tubulin Inhibitors
12. Competitive Landscape
- Abraxis Biosciences
- Agensys
- Amgen
- Celgene
- Eagle Pharmaceuticals
- Endocyte
- Genentech
- Immunogen
- Modra Pharmaceuticals
- Pierre Fabre
- Roche
- Sanofi-Aventis
- Seattle Genetics
- Tocris Bioscience
For more information about this clinical trials report visit https://www.researchandmarkets.com/research/hr774n/global_cancer?w=4.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005757/en/
Contacts:
ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials